Literature DB >> 12396958

Efficacy of the eradication of Helicobacter pylori infection in patients with chronic urticaria. A placebo-controlled double blind study.

P Gaig1, P García-Ortega, E Enrique, M Papo, J C Quer, C Richard.   

Abstract

Helicobacter pylori has been involved in the pathogenesis of chronic idiopathic urticaria (CIU) in patients suffering both CIU and H. pylori infection. We selected 49 patients with 13C urea breath test positive, long-lasting CIU and H. pylori infection; 20 remained symptomatic, had positive urease test or H. pylori histologic identification in gastric biopsy material and accepted to participate in a pacebo-controlled treatment trial. They were randomized for a 7-day, double-blind, placebo-controlled H. pylori eradication treatment with amoxicillin, clarithromycin and omeprazol or placebo. H. pylori eradication was assessed by a second 13C urea breath test six weeks after the end of treatment. We observed a significant improvement of more than 70 % of CIU; baseline clinical score was seen in 4 of the 9 (44 %) patients who eradicated H. pylori after active treatment and in 1 of the 7 (12,3 %) of those who did not (p = 0.19). No clinical differences in CIU characteristics were found between patients with and without improvement. No serious adverse effects were observed in either treatment group. We conclude that the eradication of H. pylori may be useful for patients suffering long-lasting CIU and H. pylori infection, although theses results did not reach statistical significance probably owing to the strict conditions of the recruitment.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12396958     DOI: 10.1016/s0301-0546(02)79133-7

Source DB:  PubMed          Journal:  Allergol Immunopathol (Madr)        ISSN: 0301-0546            Impact factor:   1.667


  9 in total

1.  Celiac disease and chronic urticaria resolution: a case report.

Authors:  M Candelli; E C Nista; M Gabrielli; L Santarelli; G Pignataro; G Cammarota; Giovanni Gasbarrini; Antonio Gasbarrini
Journal:  Dig Dis Sci       Date:  2004-09       Impact factor: 3.199

Review 2.  Helicobacter pylori and skin autoimmune diseases.

Authors:  Eli Magen; Jorge-Shmuel Delgado
Journal:  World J Gastroenterol       Date:  2014-02-14       Impact factor: 5.742

Review 3.  Helicobacter pylori and autoimmune disease: cause or bystander.

Authors:  Daniel S Smyk; Andreas L Koutsoumpas; Maria G Mytilinaiou; Eirini I Rigopoulou; Lazaros I Sakkas; Dimitrios P Bogdanos
Journal:  World J Gastroenterol       Date:  2014-01-21       Impact factor: 5.742

4.  The Clinical Correlations of Helicobacter pylori Virulence Factors and Chronic Spontaneous Urticaria.

Authors:  Yi-Chun Chiu; Wei-Chen Tai; Seng-Kee Chuah; Ping-I Hsu; Deng-Chyang Wu; Keng-Liang Wu; Chao-Cheng Huang; Ji-Chen Ho; Johannes Ring; Wen-Chieh Chen
Journal:  Gastroenterol Res Pract       Date:  2013-07-16       Impact factor: 2.260

5.  Role of Helicobacter pylori Eradication in Chronic Spontaneous Urticaria: A Propensity Score Matching Analysis.

Authors:  Yan Guo; Hua-Ming Li; Wei-Qin Zhu; Zhen Li
Journal:  Clin Cosmet Investig Dermatol       Date:  2021-02-05

Review 6.  The Effects of Antibiotics for Helicobacter pylori Eradication or Dapsone on Chronic Spontaneous Urticaria: A Systematic Review and Meta-Analysis.

Authors:  Jun Watanabe; Junya Shimamoto; Kazuhiko Kotani
Journal:  Antibiotics (Basel)       Date:  2021-02-04

7.  Urticaria and infections.

Authors:  Bettina Wedi; Ulrike Raap; Dorothea Wieczorek; Alexander Kapp
Journal:  Allergy Asthma Clin Immunol       Date:  2009-12-01       Impact factor: 3.406

Review 8.  Causal inference regarding infectious aetiology of chronic conditions: a systematic review.

Authors:  Sofia Orrskog; Emma Medin; Svetla Tsolova; Jan C Semenza
Journal:  PLoS One       Date:  2013-07-25       Impact factor: 3.240

9.  Eradication of Helicobacter pylori, as add-on therapy, has a significant, but temporary influence on recovery in chronic idiopathic urticaria: a placebo-controlled, double blind trial in the Polish population.

Authors:  Robert Pawłowicz; Krzysztof Wytrychowski; Bernard Panaszek
Journal:  Postepy Dermatol Alergol       Date:  2018-04-24       Impact factor: 1.837

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.